We thus set up a retrospective observational multicenter study (named SAVIMMUNE RETRO) designed to collect clinical features, PD-L1 status, response to therapy, and outcomes in a cohort of advanced NSCLC patients with very poor PS that were treated using salvage nivolumab. The gene discussed is CD274; the disease is non-small cell lung carcinoma.